Search PubMed⌕ Search

Biomedical subjects

V N Vahia

Publications and source records attributed to V N Vahia.

8 recordsLinked to original sources

Suicide and depression.

Suicide is considered to be a symptom or sequel of depression. Depressive patients (15-20%) die after committing suicide. Aetiology of suicide comprises social factors, psychological factors and biological factors. Suicide, ideational or operational must receive immediate therapeutic attention. Pharmacotherapy, electroconvulsive therapy constitute the management of suicide--Preventive strategies include primary, secondary or tertiary preventions.

Antidepressive Agents↗

Tardive dyskinesia in India: a prevalence study.

We screened the entire inpatient population (N = 1963) of a state hospital near Bombay, India, for tardive dyskinesia (TD) using specific diagnostic criteria. Prevalence of TD was found to be 9.6%, which was much lower than that reported from the Western countries. Percent prevalence of TD was greatest in the age group 41 to 50, after which it seemed to decline. TD patients had received neuroleptic treatment for significantly longer periods and in significantly greater amounts than non-TD patients. The principal reason for the relatively low prevalence of TD in India is probably the practice of using neuroleptics in comparatively small doses (mean daily dose is about 200 mg of chlorpromazine equivalents). A possible contribution of racial-genetic factors cannot be excluded.

Adult↗

Effects of intravenous metoclopramide in 81 patients with tardive dyskinesia.

We compared acute effects of single intravenous administrations of metoclopramide (40 mg) and placebo in a double-blind crossover study involving 81 patients with tardive dyskinesia. Metoclopramide produced significantly greater reduction in mean total Abnormal Involuntary Movement Scale score as well as in ratings for six of the seven body areas, when compared with placebo. On adjusting each patient's metoclopramide response for his or her placebo response, we found that 35 of the 81 patients had 50% or greater placebo-corrected improvement. There were no apparent clinical differences between metoclopramide responders and nonresponders. Administration of 60 mg of metoclopramide to 15 patients produced greater improvement in tardive dyskinesia as compared with 40 mg; the incidence of acute dystonia, however, jumped from 10% with 40 mg to 33% with 60 mg.

Adult↗